Flickr Creative Commons

If policymakers offer a short-term extension of monopoly pricing for old drugs to treat rare diseases, drug companies could reap a lot of profits quickly at the expense of the public, according to a new study by Harvard physicians in the journal Health Affairs.

What they found: Researchers looked at 13 drugs, like AbbVie's blockbuster Humira, that later gained supplemental approval as "orphan drugs" for people with rare diseases. They modeled what the financial returns would look like with a six-month extension of monopoly pricing in proposed federal legislation. The median net returns would have surpassed $82 million.

The money quote: "The incentives offered under the [legislation] would serve as windfalls to manufacturers that would have sought approval of their drugs for relevant rare disease populations even without those incentives." Instead, researchers said policymakers should consider just covering the cost of clinical trials or offering tax credits in the place of the full-blown market exclusivity extension.

Perfect timing: The study coincides with a major Kaiser Health News investigation that found drug companies routinely repurpose blockbuster drugs as orphan medicines to milk more sales and profits from new market exclusivity.

Go deeper

Updated 1 hour ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 7 p.m. ET: 30,881,522 — Total deaths: 958,493— Total recoveries: 21,119,006Map.
  2. U.S.: Total confirmed cases as of 7 p.m. ET: 6,794,479 — Total deaths: 199,469 — Total recoveries: 2,590,671 — Total tests: 95,108,559Map.
  3. Politics: Testing czar on Trump's CDC contradictions: "Everybody is right" Ex-FDA chief: Career scientists won't be "easily cowed" by political vaccine pressure.
  4. Education: What we overlooked in the switch to remote learning.
  5. Health: The dwindling chances of eliminating COVID-19 — 7 states set single-day coronavirus case records last week.
  6. World: England sets £10,000 fine for breaking self-isolation rules — The countries painting their pandemic recoveries green.

Trump campaign goes all in on Pennsylvania

Trump poster in Scranton, Pennsylvania. Photo: Robert Nickelsberg/Getty Images

The president's campaign is placing more importance on Pennsylvania amid growing concern that his chances of clinching Wisconsin are slipping, Trump campaign sources tell Axios.

Driving the news: Pennsylvania, which has 20 electoral votes, twice Wisconsin's number, actually has been trending higher in recent public and internal polling, a welcome development for the campaign.

Inside Biden's Supreme Court strategy

Joe Biden enters the hall at the National Constitution Center. Photo: Roberto Schmidt/AFP via Getty Images

Joe Biden’s closing argument will shift to a dominant emphasis on health care, turning the looming Supreme Court fight into a referendum on coverage and pre-existing conditions, officials tell Axios.

Why it matters: Biden aides believed they were winning when the race was about the coronavirus pandemic. Now they plan to use the Supreme Court opening as a raucous new field for a health care fight, returning to a theme that gave Democrats big midterm wins in 2018.